Design Therapeutics Statistics
Total Valuation
DSGN has a market cap or net worth of $900.55 million. The enterprise value is $695.82 million.
| Market Cap | 900.55M |
| Enterprise Value | 695.82M |
Important Dates
The last earnings date was Monday, August 3, 2026, before market open.
| Earnings Date | Aug 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DSGN has 62.58 million shares outstanding. The number of shares has increased by 5.61% in one year.
| Current Share Class | 62.58M |
| Shares Outstanding | 62.58M |
| Shares Change (YoY) | +5.61% |
| Shares Change (QoQ) | +1.74% |
| Owned by Insiders (%) | 14.08% |
| Owned by Institutions (%) | 47.89% |
| Float | 33.00M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.46 |
| P/TBV Ratio | 4.46 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 18.86, with a Debt / Equity ratio of 0.01.
| Current Ratio | 18.86 |
| Quick Ratio | 18.61 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -34.13% and return on invested capital (ROIC) is -23.53%.
| Return on Equity (ROE) | -34.13% |
| Return on Assets (ROA) | -22.53% |
| Return on Invested Capital (ROIC) | -23.53% |
| Return on Capital Employed (ROCE) | -38.92% |
| Weighted Average Cost of Capital (WACC) | 13.23% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.29M |
| Employee Count | 55 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +188.96% in the last 52 weeks. The beta is 1.64, so DSGN's price volatility has been higher than the market average.
| Beta (5Y) | 1.64 |
| 52-Week Price Change | +188.96% |
| 50-Day Moving Average | 12.90 |
| 200-Day Moving Average | 10.98 |
| Relative Strength Index (RSI) | 62.61 |
| Average Volume (20 Days) | 436,785 |
Short Selling Information
The latest short interest is 5.95 million, so 9.51% of the outstanding shares have been sold short.
| Short Interest | 5.95M |
| Short Previous Month | 5.67M |
| Short % of Shares Out | 9.51% |
| Short % of Float | 18.04% |
| Short Ratio (days to cover) | 8.41 |
Income Statement
| Revenue | n/a |
| Gross Profit | -58.78M |
| Operating Income | -78.96M |
| Pretax Income | -70.80M |
| Net Income | -70.80M |
| EBITDA | -79.36M |
| EBIT | -79.36M |
| Earnings Per Share (EPS) | -$1.18 |
Balance Sheet
The company has $207.40 million in cash and $2.66 million in debt, with a net cash position of $204.73 million or $3.27 per share.
| Cash & Cash Equivalents | 207.40M |
| Total Debt | 2.66M |
| Net Cash | 204.73M |
| Net Cash Per Share | $3.27 |
| Equity (Book Value) | 201.86M |
| Book Value Per Share | 3.23 |
| Working Capital | 200.77M |
Cash Flow
In the last 12 months, operating cash flow was -$55.08 million and capital expenditures -$55,000, giving a free cash flow of -$55.14 million.
| Operating Cash Flow | -55.08M |
| Capital Expenditures | -55,000 |
| Depreciation & Amortization | 619,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -55.14M |
| FCF Per Share | -$0.88 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DSGN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.61% |
| Shareholder Yield | -5.61% |
| Earnings Yield | -7.86% |
| FCF Yield | -6.12% |
Analyst Forecast
The average price target for DSGN is $21.00, which is 45.94% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $21.00 |
| Price Target Difference | 45.94% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |